معرفی
Karl Griswold is a Professor of Engineering at Dartmouth College's Thayer School of Engineering, where he leads the Griswold Research Group focused on protein engineering and biotherapeutics development. His interdisciplinary work spans chemical, biological, and engineering disciplines to address critical challenges in drug-resistant infections and protein therapeutics.
Education:
- BS in Chemistry from Southwest Texas State University (1995)
- PhD in Chemistry from the University of Texas at Austin (2005)
Research Focus:
Professor Griswold's laboratory specializes in protein engineering, directed evolution, and biotherapeutics development, creating novel biomolecules with superior functionality compared to natural proteins. The group develops high-throughput screening methods, protein deimmunization strategies, enhanced expression systems, and antibacterial agents targeting drug-resistant infections. Their work has significant translational potential for treating conditions like MRSA and Pseudomonas aeruginosa infections.
Scientific Recognition:
- Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008)
- NIH Biotechnology Training Grant (2000-2003)
- Royston M. Roberts - Regents Fellowship, University of Texas (1999)
- DOW Chemical Foundation Scholar, Texas State University (1991-1995)
- Senior Fellow, National Academy of Inventors
Research Leadership:
As co-founder and CEO of Stealth Biologics, Professor Griswold translates academic research into commercial applications. His work has secured NIH funding and Dartmouth Innovations Accelerator support, with research featured in Chemical & Engineering News, Vermont Public Radio, and the New Hampshire Union Leader for developing alternatives to traditional antibiotics.
Research Environment:
The Griswold Research Group maintains extensive collaborations across disciplines including clinical medicine, immunology, structural biology, and chemical engineering. This interdisciplinary approach prepares trainees for careers at the intersection of multiple scientific fields, with research focusing on Biomolecular Antimicrobial Therapies, Deimmunizing Protein Therapeutics, and Gene Library Construction Technologies.
